Published

Psilocybin-induced neurocardiogenic syncope: a case report

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Psychopharmacology
Date: 2026-05-28
Source: Crossref
DOI: 10.1007/s00213-026-07079-8
PubMed: 42207275

Authors

Atiq Mazen A.Weisman Eli Guerra Rodrigo B.Martinez Luis Luna Yaden David B.Barrett Frederick S.Nayak Sandeep Sayali Ceyda

Watch author

Derived topics and classifications

psilocybin Anxiety Brain Imaging Consciousness Aging Emotional Processing Clinical Trial Case Report Safety Adverse Events Clinical Trial

Citation graph

9 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

10.1176/appi.ajp.20250037 10.1007/s00213-006-0457-5 10.1161/circulationaha.104.482018 10.1001/jamapsychiatry.2024.2546 10.1177/02698811221084063 10.1161/01.cir.102.23.2898 10.1016/j.euroneuro.2023.07.011 10.1089/psymed.2023.0046 10.1001/jamanetworkopen.2024.5960

Indexed papers citing this DOI

Psilocybin-induced neurocardiogenic syncope: a case report2026-05-28

Related papers

S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy SubjectsClinicalTrials.gov · 2024-01-24 Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy SubjectsClinicalTrials.gov · 2020-12-01 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderClinicalTrials.gov · 2025-08-19 Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28